Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Rhea-AI Summary

Cue Biopharma, Inc. (Nasdaq: CUE) is set to present at the 20th PEGS Boston Summit with two poster presentations discussing their innovative Immuno-STAT biologics for targeting autoimmune diseases and immuno-oncology. The presentations will cover the CUE-500 series for depleting B cells in autoimmune diseases and the Immuno-STAT platform for cancer and inflammatory diseases.

Positive

• Cue Biopharma showcasing their novel therapeutic biologics at a prestigious event like the 20th PEGS Boston Summit highlights their commitment to innovation and advancing treatment options for various diseases.

• The development of the CUE-500 series and Immuno-STAT platform demonstrates Cue Biopharma's dedication to addressing unmet medical needs in autoimmune diseases, immuno-oncology, and inflammatory conditions.

• Dr. Nitin Kumar and Dr. Ahmet Vakkasoglu presenting the poster sessions on Cue Biopharma's cutting-edge biologics signifies the company's expertise and progress in the field of targeted immunotherapy.

Negative

• None.

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.

Presentation Details

Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDT
Session: Poster Session A
Poster number: A028
Title: Immuno-STATs for Targeted Depletion of B Cells in Autoimmune Diseases
Presenter: Nitin Kumar, Scientist, Biologics Discovery and Innovation, Cue Biopharma

Dr. Kumar will discuss Cue Biopharma’s newly deployed CUE-500 series of bispecific Immuno-STAT™ biologics, designed to redirect and activate cytotoxic anti-viral memory T cells to deplete pathogenic B cells, which is a therapeutically relevant mechanism for the treatment of several autoimmune diseases.

Date and Time: Tuesday, May 14 from 2:00 p.m. – 4:00 p.m. and Wednesday, May 15 from 9:00 a.m. – 7:30 p.m. EDT
Session: Poster Session B
Poster number: B023
Title: Immuno-STATs (ISTs): A Novel and Unique T-Cell Engager Platform for the Treatment of Immuno-Oncology and Autoimmune Diseases
Presenter: Ahmet Vakkasoglu, Associate Director, Biologics Discovery and Innovation, Cue Biopharma

Dr. Vakkasoglu will present an overview of Cue Biopharma’s Immuno-STAT™ platform and biologics. This will include a discussion of our lead oncology assets, which have demonstrated clinical anti-tumor activity, as well as an overview of our next generation platforms and molecules for the treatment of cancer, autoimmune and inflammatory diseases.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com 

FAQ

What is Cue Biopharma presenting at the 20th PEGS Boston Summit?

Cue Biopharma will deliver two poster presentations discussing their Immuno-STAT biologics for targeting autoimmune diseases and immuno-oncology.

When will Cue Biopharma's presentations take place at the summit?

Cue Biopharma's presentations are scheduled for Monday, May 13 and Tuesday, May 14 at specific times during the 20th PEGS Boston Summit.

Who will be presenting Cue Biopharma's biologics at the summit?

Dr. Nitin Kumar and Dr. Ahmet Vakkasoglu will be presenting Cue Biopharma's novel biologics at the 20th PEGS Boston Summit.

What is the focus of Cue Biopharma's CUE-500 series of biologics?

The CUE-500 series is designed for the targeted depletion of B cells in autoimmune diseases, providing a therapeutically relevant mechanism for treatment.

What is Cue Biopharma's Immuno-STAT platform used for?

Cue Biopharma's Immuno-STAT platform is utilized for the treatment of cancer, autoimmune, and inflammatory diseases, offering unique T-cell engagement capabilities.